Status:
RECRUITING
A Study of Chidamide With AZA in MRD Positive AML After Transplant
Lead Sponsor:
Guangdong Provincial People's Hospital
Collaborating Sponsors:
Shenzhen Chipscreen Biosciences Co.Ltd
Conditions:
AML, Adult
Minimal Residual Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSC...
Detailed Description
Investigators proposed Chidamide combined with azacitidine as the prospective treatment for MRD-positive AML patients before and after transplantation, hoping to reduce the recurrence rate of transpla...
Eligibility Criteria
Inclusion
- Patients diagnosed with AML (diagnostic criteria refer to WHO2016 criteria, except M3) can detect small residual lesions (MRD) positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT);
- ≥18 years old;
- ECOG≤3;
- lifespan≥3 months;
- Take contraceptive measures;
- Sign informed consent.
Exclusion
- Allergic to the study drug;
- A gastrointestinal condition that prevents oral medication;
- active infection;
- Dysfunction of vital organs;
- other malignancies;
- HIV infection;
- HBV or HCV;
- The QT interval is prolonged;
- Pregnant or lactating women;
- Is participating in other clinical studies;
- The researchers did not consider it appropriate to participate in this study.
Key Trial Info
Start Date :
October 26 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06066905
Start Date
October 26 2023
End Date
December 1 2026
Last Update
October 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China